Intravenous immunoglobulin a natural regulator of immunity and inflammation

Transplantation

Volumn 88, Issue 1, 2009, Pages 1-6

  Jordan, Stanley C ^a   Toyoda, Mieko ^a   Vo, Ashley A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Alloimmunity; Cell mediated immunity; Complement; Inflammation; IVIG

Indexed keywords

ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ALLOIMMUNITY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; DESENSITIZATION; DRUG MEGADOSE; GRAFT REJECTION; HUMAN; IMMUNE INJURY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; ALLOTRANSPLANTATION; ANIMAL; DRUG EFFECT; IMMUNOLOGY; METHODOLOGY; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE;

ANIMALS; COMPLEMENT ACTIVATION; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFLAMMATION; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 67651027514     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a9e89a     Document Type: Review

References (45)

1. Nimmerjahn F, Ravetch J. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513.
2. Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun Rev 2006; 5: 465.
3. Tha-In T, Bayry J, Metsellar H, et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29: 608.
4. Hartnug HP. Advances in the understanding of the mechanisms of action of IVIg. J Neurol 2008; 255: 3.
5. Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol 2007; 19: 646.
6. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800.
7. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53.
8. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72: 419.
9. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly HLA-sensitized adult patients with end stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
10. Kaveri S, Lacroix-Desmazes S, Bayry J. The anti-inflammatory IgG. N Engl J Med 2008; 359: 307.
11. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
12. Arumugam TV, Woodruff TM, Lathia JD, et al. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience. 2008; 158: 1074.
13. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176: 1305.
14. Arumugam TV, Shiels IA, Woodruff TM, et al. The role of the complement system in ischemia-reperfusion injury. Shock 2004; 21: 401.
15. Degan SE, Thiel S, Jensenius JC. New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology 2007; 212: 301.
16. Wills-Karp M. Complement activation pathways: A bridge between innate and adaptive immune responses in asthma. Proc Am Thorac Soc 2007; 4: 247.
17. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: A new complement activation pathway. Nat Med 2006; 12: 682.
18. Kemper C, Atkinson JP. T-cell regulation: With complements from innate immunity. Nat Rev Immunol 2007; 7: 9.
19. Basta M. Ambivalent effect of immunoglobulin on the complement system: Activation versus inhibition. Mol Immunol 2008; 45: 4073.
20. Thurman J. Triggers of inflammation after renal ischemia/reperfusion injury. Clin Immunol 2007; 123: 7.
21. Arumugam TV, Tang SC, Lathia JD, et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci USA 2007; 104: 14104.
22. Arumugam TV, Selvaraj PK, Woodruff TM, et al. Targeting ischemic brain injury with intravenous immunoglobulin. Expert Opin Ther Targets 2008; 12: 19.
23. ′2-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins. Nat Med 2003; 9: 431.
24. Park-Min KH, Serbina NV, Yang W, et al. Fc gamma RIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007; 26: 67.
25. Sameulsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 29: 484.
26. Kaneko Y, Nimmerjahn F, Madaio M, et al. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exper Med 2006; 203: 789.
27. Anthony RM, Nimmerjahn F, Ashline DJ, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373.
28. Kaneko Y, Nimmerjahn F, Ravetch J. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670.
29. Anthony RM, Wermeling F, Karlsson MC, et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105: 19571.
30. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 2000; 18: 739.
31. Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715.
32. Nimmerjahn F, Ravetch JV. Fcγreceptors: Old friends and new family members. Immunity 2006; 24: 19.
33. Ravetch JV, Clynes RA. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998; 16: 421.
34. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758.
35. Tha-In T, Metselaar HJ, Tilanus HW, et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: Comparison to calcineurin inhibitors. Transplantation 2006; 81: 1725.
36. Smed-Sorensen A, Moll M, Cheng TY, et al. IgG regulates the CD1 expression profile and lipid antigen presenting function in human dendritic cells via FcγRIIa. Blood 2008; 111: 5037.
37. Abe J, Jibiki T, Noma S, et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 2005; 174: 5837.
38. Gill V, Doig C, Knight D, et al. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005; 112: 2031.
39. Turhan A, Jenab P, Bruhns P, et al. Intravenous gammaglobulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 2004; 103: 2397.
40. Toyoda M, Pao A, Petrosian A, et al. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003; 3: 156.
41. Toyoda M, Zhang XM, Petrosian A, et al. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gammaglobulin. Transplant Immunol 1994; 2: 337.
42. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T-regulatory cells by increasing their suppressive function. J Immunol 2007; 179: 5571.
43. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes." Blood 2008; 112: 3303.
44. Jordan SC, Pescovits M. Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421.
45. Vo A, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Eng J Med 2008; 359: 242.